Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Swedish Orphan Biovitrum AB Sobi
Swedish Orphan Biovitrum AB Sobi
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Therapeutic: efanesoctocog alfa for haemophilia A
Haemophilia A is a rare genetic disorder in which the blood cannot clot properly; this is caused by a lack of factor VIII, one of the proteins involved in the clotting cascade
Recruitment
Sobi appoints Head of Technical Operations
Research & Development
Sobi Orfadin capsules approved in Saudi Arabia
Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Estates & Facilities
Sobi opens office in Greece
The company is welcomed by those hoping for innovative therapeutic solutions in Greece
Regulatory
Sobi’s Elocta approved in Switzerland for the treatment of haemophilia A
Elocta is indicated for both on-demand and prophylaxis treatment of people with haemophilia A of all ages
Manufacturing
Sobi signs manufacturing agreements with Pfizer
Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Chief Medical Officer Birgitte Volck to leave Sobi
To join GlaxoSmithKline as Head of R&D Rare Diseases
Subscribe now